ProSci SARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Peptide (Omicron)

Catalog No.	Quantity
16-595-514	0.05 mg

Catalog No. 16-595-514 Supplier ProSci Supplier No. 9793P0050

Description

Used for Blocking Activity

SARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Peptide (Omicron)is used for blocking the activity of theSARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Antibody (Omicron)

SARS-CoV-2 Omicron variant, a variant of concern (VOC), known as B.1.1.529, was detected in South Africa at the end of November in 2021. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 90% of the new cases. Omicron variant spike protein carries around 30 amino acid changes, including mutations, deletions and insertions, 15 of which are in the receptor binding domain (RBD). Enhanced transmission of the Omicron variant was observed globally, which is at least 70 times more contagious than the other variants. The Omicron variant affects the effectiveness of COVID-19 vaccine and is resistant to neutralization (monoclonal antibody treatments) to a large extent.

Specifications

• Gene ID (Entrez): 43740568
• Species: SARS-CoV-2
• Accession Number: QHD43416
• Common Name: surface glycoprotein
• Concentration: 200 μg/mL
• Content And Storage: Store SARS-CoV-2 (COVID-19) Spike G142D Δ143-145 VYY Peptide (Omicron) (at -20°C, stable for one year.)
• Format: Liquid
• Formulation: PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide
• For Use With (Application): Blocking Assay
• Gene Symbol: S
• Quantity: 0.05 mg
• Sequence: 12 amino acids near the amino terminus of SARS-CoV-2 (COVID-19) Spike G142D Δ143-145 VYY (Omicron).
• Synonym: SARS-CoV-2 Omicron Variant Spike antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein, Omicron Variant